Antibody-Mediated Rejection Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies - CSL Behring, Hansa Biopharma, Talaris Therapeutics, ICON Clinical Research, NYU Langone Health

DelveInsight's "Antibody-Mediated Rejection Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Antibody-Mediated Rejection, historical and forecasted epidemiology as well as the Antibody-Mediated Rejection market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Antibody-Mediated Rejection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Antibody-Mediated Rejection Market Forecast
https://www.delveinsight.com/report-store/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Antibody-Mediated Rejection Market Report:
• The Antibody-Mediated Rejection market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• Antibody-Mediated Rejection (AMR) cases totaled 5,102 in 7MM countries in 2021, and this number is anticipated to rise at a modest CAGR from 2019 to 2032
• The country with the highest incident population of AMR cases, according to DelveInsight projections, was the United States. AMR instances totaled 3,327 in the US in 2021, and according to DelveInsight's projections, this number would rise at a moderate CAGR through 2032
• France had the highest number of antibody-mediated rejection (AMR) cases among the European nations in 2021, with 407 instances, followed by Spain with 372 cases. Italy, on the other hand, had the fewest cases in 2021, with only 236 cases
• Key Antibody-Mediated Rejection Companies: CSL Behring, Hansa Biopharma, Talaris Therapeutics, ICON Clinical Research, NYU Langone Health, Farsad Eskandary, Bristol-Myers Squibb, Alexion, and others
• Key Antibody-Mediated Rejection Therapies: Clazakizumab, Idefirix (imlifidase), FCR001, Physiologic saline solution, C1-INH (Berinert), Felzartamab, Belatacept, Eculizumab, and others
• The Antibody-Mediated Rejection market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Antibody-Mediated Rejection pipeline products will significantly revolutionize the Antibody-Mediated Rejection market dynamics.

Antibody-Mediated Rejection Overview
Following organ transplantation, antibody-mediated rejection (AMR) is a serious issue that can cause both short- and long-term damage to transplant recipients. Up to one-third of severely sensitized recipients may experience acute AMR after transplantation, despite desensitization measures. AMR is also a major worry in non-sensitized persons since de novo DSAs might appear soon after transplantation or years later.

Get a Free sample for the Antibody-Mediated Rejection Market Report
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Antibody-Mediated Rejection Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Antibody-Mediated Rejection Epidemiology Segmentation:
The Antibody-Mediated Rejection market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Antibody-Mediated Rejection
• Prevalent Cases of Antibody-Mediated Rejection by severity
• Gender-specific Prevalence of Antibody-Mediated Rejection
• Diagnosed Cases of Episodic and Chronic Antibody-Mediated Rejection

Download the report to understand which factors are driving Antibody-Mediated Rejection epidemiology trends @ Antibody-Mediated Rejection Epidemiology Forecast
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Antibody-Mediated Rejection Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Antibody-Mediated Rejection market or expected to get launched during the study period. The analysis covers Antibody-Mediated Rejection market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Antibody-Mediated Rejection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Antibody-Mediated Rejection Therapies and Key Companies
• Clazakizumab: CSL Behring
• Idefirix (imlifidase): Hansa Biopharma
• FCR001: Talaris Therapeutics
• Physiologic saline solution: ICON Clinical Research
• C1-INH (Berinert): NYU Langone Health
• Felzartamab: Farsad Eskandary
• Belatacept: Bristol-Myers Squibb
• Eculizumab: Alexion

Discover more about therapies set to grab major Antibody-Mediated Rejection market share @ Antibody-Mediated Rejection Treatment Market
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Antibody-Mediated Rejection Market Drivers
• Introduction of non-invasive biomarkers
• Rising organ donation rate
• Changes in the treatment paradigm

Antibody-Mediated Rejection Market Barriers
• Increasing healthcare burden
• Challenges in designing clinical trials
• Safety concerns of available treatment

Scope of the Antibody-Mediated Rejection Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Antibody-Mediated Rejection Companies: CSL Behring, Hansa Biopharma, Talaris Therapeutics, ICON Clinical Research, NYU Langone Health, Farsad Eskandary, Bristol-Myers Squibb, Alexion, and others
• Key Antibody-Mediated Rejection Therapies: Clazakizumab, Idefirix (imlifidase), FCR001, Physiologic saline solution, C1-INH (Berinert), Felzartamab, Belatacept, Eculizumab, and others
• Antibody-Mediated Rejection Therapeutic Assessment: Antibody-Mediated Rejection current marketed and Antibody-Mediated Rejection emerging therapies
• Antibody-Mediated Rejection Market Dynamics: Antibody-Mediated Rejection market drivers and Antibody-Mediated Rejection market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Antibody-Mediated Rejection Unmet Needs, KOL's views, Analyst's views, Antibody-Mediated Rejection Market Access and Reimbursement

To know more about Antibody-Mediated Rejection companies working in the treatment market, visit @ Antibody-Mediated Rejection Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/antibody-mediated-rejection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Antibody-Mediated Rejection Market Report Introduction
2. Executive Summary for Antibody-Mediated Rejection
3. SWOT analysis of Antibody-Mediated Rejection
4. Antibody-Mediated Rejection Patient Share (%) Overview at a Glance
5. Antibody-Mediated Rejection Market Overview at a Glance
6. Antibody-Mediated Rejection Disease Background and Overview
7. Antibody-Mediated Rejection Epidemiology and Patient Population
8. Country-Specific Patient Population of Antibody-Mediated Rejection
9. Antibody-Mediated Rejection Current Treatment and Medical Practices
10. Antibody-Mediated Rejection Unmet Needs
11. Antibody-Mediated Rejection Emerging Therapies
12. Antibody-Mediated Rejection Market Outlook
13. Country-Wise Antibody-Mediated Rejection Market Analysis (2019-2032)
14. Antibody-Mediated Rejection Market Access and Reimbursement of Therapies
15. Antibody-Mediated Rejection Market Drivers
16. Antibody-Mediated Rejection Market Barriers
17. Antibody-Mediated Rejection Appendix
18. Antibody-Mediated Rejection Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Related Reports:
Antibody-Mediated Rejection Epidemiology https://www.delveinsight.com/report-store/antibody-mediated-rejection-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Antibody-Mediated Rejection Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Antibody-Mediated Rejection epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.